Anokion SA   Report issue

For profit Phase 1 Phase 2
Founded: Ecublens Switzerland (2010)

Organization Overview

First Clinical Trial
2020
NCT04602390
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Anokion SA

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: Anokion SA (0) Acquired (1)

kan-101 (2 trials)

Drugs in Phase 1 Trials (1)

ank-700 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2